Asthma quality of life questionnaire score (pooled data) in Asian and non-Asian patients, at baseline and after 52 weeks of treatment. (DOCX 112 kb
e-table 1: Characteristics of the studies and treatment arms included in the MTC. e-table 2: Results...
Plot of serious pneumonia incidence per 1000 patient-years and 95% CI by treatment group (integrated...
Scoring for severity of asthma modified by Eisnerâs method. Table S2: Pearson correlation coeffici...
Summary of the most common adverse events (âĽ5%) in the Asian and non-Asian populations. (DOCX 24 k...
Profile of the three Phase III studies included in both the efficacy and safety analyses. (DOCX 47.4...
Adjusted treatment differences from baseline in trough FEV1 at Week 12 (Efficacy population). (DOCX ...
AEs reported by âĽ3 patients in the Japan+Korea cohort of any relevant treatment arm and the corres...
Region ratios of ‘treatment effect’ in Japan+Korea and Not-Japan+Korea patients, where ‘treatment ef...
Profile of the two additional Phase IIb studies included in only the safety analyses. (DOCX 25.6 KB
Scatter plot of ACQ and miniAQLQ scores. Table S1. Characteristics of asthma. Table S2. Lung functio...
List of Institutions and Independent Ethics Committees/Institutional Review Boards for Studies HZA10...
International audienceBACKGROUND: To analyse the efficacy of fluticasone propionate (FP) alone and c...
Table S1. Standardized asthma history obtained by study physicians at both study visits. Table S2. C...
Flowchart of the study population. Detailed information on characteristics and co-medication of case...
Table S2. Â Odd ratios of association between comorbid conditions on ICS to total medications <â50...
e-table 1: Characteristics of the studies and treatment arms included in the MTC. e-table 2: Results...
Plot of serious pneumonia incidence per 1000 patient-years and 95% CI by treatment group (integrated...
Scoring for severity of asthma modified by Eisnerâs method. Table S2: Pearson correlation coeffici...
Summary of the most common adverse events (âĽ5%) in the Asian and non-Asian populations. (DOCX 24 k...
Profile of the three Phase III studies included in both the efficacy and safety analyses. (DOCX 47.4...
Adjusted treatment differences from baseline in trough FEV1 at Week 12 (Efficacy population). (DOCX ...
AEs reported by âĽ3 patients in the Japan+Korea cohort of any relevant treatment arm and the corres...
Region ratios of ‘treatment effect’ in Japan+Korea and Not-Japan+Korea patients, where ‘treatment ef...
Profile of the two additional Phase IIb studies included in only the safety analyses. (DOCX 25.6 KB
Scatter plot of ACQ and miniAQLQ scores. Table S1. Characteristics of asthma. Table S2. Lung functio...
List of Institutions and Independent Ethics Committees/Institutional Review Boards for Studies HZA10...
International audienceBACKGROUND: To analyse the efficacy of fluticasone propionate (FP) alone and c...
Table S1. Standardized asthma history obtained by study physicians at both study visits. Table S2. C...
Flowchart of the study population. Detailed information on characteristics and co-medication of case...
Table S2. Â Odd ratios of association between comorbid conditions on ICS to total medications <â50...
e-table 1: Characteristics of the studies and treatment arms included in the MTC. e-table 2: Results...
Plot of serious pneumonia incidence per 1000 patient-years and 95% CI by treatment group (integrated...
Scoring for severity of asthma modified by Eisnerâs method. Table S2: Pearson correlation coeffici...